This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Phreesia (PHR) and Novo Nordisk (NVO)

Tipranks - Tipranks - Tue Jun 23, 7:30AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phreesia (PHR) and Novo Nordisk (NVO).

TipRanks' Prime Week Sale - 70% Off

Phreesia (PHR)

BMO Capital analyst Sean Dodge maintained a Buy rating on Phreesia today and set a price target of $14.00. The company’s shares closed last Thursday at $9.38.

According to TipRanks.com, Dodge is ranked 0 out of 5 stars with an average return of -6.0% and a 40.7% success rate. Dodge covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Aveanna Healthcare Holdings, and Lifestance Health Group. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Phreesia with a $14.33 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Novo Nordisk (NVO)

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk today and set a price target of $45.00. The company’s shares closed last Thursday at $43.19.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 7.0% and a 52.4% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and ACADIA Pharmaceuticals. ;'>

Novo Nordisk has an analyst consensus of Hold, with a price target consensus of $46.00.

Read More on PHR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).